Future Treatment Strategies in Retinal Vascular Diseases

In the final episode, “Future Treatment Strategies in Retinal Vascular Diseases,” the panelists explored the emerging therapeutic landscape and the future of retinal vascular disease management. The expert faculty discussed how novel treatment modalities, including tyrosine kinase inhibitors (TKIs), gene therapy, and multi-targeted biologics, may reshape the management of AMD, DME, DR, and retinal vein occlusion over the next several years.

Throughout the discussion, the panel highlighted the growing excitement surrounding TKIs as a potential next frontier in retinal disease treatment. The expert faculty reviewed how these intracellular therapies may complement existing biologic anti-VEGF agents and potentially improve durability while reducing treatment burden. The panelists emphasized that future treatment paradigms are unlikely to rely on a single therapy alone, but instead may incorporate multiple mechanisms of action in a manner similar to oncology treatment strategies.

The panel also explored the promise and challenges of gene therapy, including the potential for sustained intraocular drug production and dramatically prolonged durability. While gene therapy remains an exciting area of development, the expert faculty noted the importance of carefully evaluating safety, inflammation, and real-world feasibility before broad adoption. In addition, the discussion addressed how future therapies may integrate into clinical practice alongside current anti-VEGF biologics rather than fully replace them.

To conclude the series, the panelists reflected on the rapid pace of innovation within retina, emphasizing the importance of remaining informed, open-minded, and engaged with evolving clinical data to continue improving patient outcomes across retinal vascular diseases. Thank you for watching this peer exchange series on retinal vascular diseases. Please subscribe to our newsletter for information on upcoming video series.